Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome
Aims: To assess the comparative effects of glucagon-like peptide-1 receptor agonists (GLP-1RA), 4-dipeptidyl peptidase inhibitors (DPP-4I), and metformin treatment during one year on metabolic syndrome (MetS) components and severity in MetS patients. Methods: Prospective study (n = 6165 adults) with...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-05-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332223003499 |
| _version_ | 1797857678927593472 |
|---|---|
| author | Cristina Bouzas Rosario Pastor Silvia Garcia Margalida Monserrat-Mesquida Miguel Ángel Martínez-González Jordi Salas-Salvadó Dolores Corella Albert Goday J. Alfredo Martínez Ángel M. Alonso-Gómez Olga Fernández-Barceló Jesús Vioque Dora Romaguera José Lopez-Miranda Ramón Estruch Francisco J. Tinahones José Lapetra Lluís Serra-Majem Blanca Riquelme-Gallego Vicente Martín-Sánchez Xavier Pintó Miguel Delgado-Rodriguez Pilar Matía Josep Vidal Jersy-Jair Cardenas-Salas Lidia Daimiel Emilio Ros Estefanía Toledo Josep M. Manzanares Inmaculada Gonzalez-Monge Miguel-Ángel Muñoz Diego Martinez-Urbistondo Lucas Tojal-Sierra Carlos Muñoz-Bravo Salvador Miralles-Gisbert Marian Martin Antonio García-Ríos Sara Castro-Barquero José Carlos Fernández-García José Manuel Santos-Lozano F. Javier Basterra-Gortari Liliana Gutiérrez-Carrasquilla Patricia Guillem-Saiz Alba Satorres Itziar Abete Carolina Sorto-Sanchez Javier Díez-Espino Nancy Babio Montse Fitó Josep A. Tur |
| author_facet | Cristina Bouzas Rosario Pastor Silvia Garcia Margalida Monserrat-Mesquida Miguel Ángel Martínez-González Jordi Salas-Salvadó Dolores Corella Albert Goday J. Alfredo Martínez Ángel M. Alonso-Gómez Olga Fernández-Barceló Jesús Vioque Dora Romaguera José Lopez-Miranda Ramón Estruch Francisco J. Tinahones José Lapetra Lluís Serra-Majem Blanca Riquelme-Gallego Vicente Martín-Sánchez Xavier Pintó Miguel Delgado-Rodriguez Pilar Matía Josep Vidal Jersy-Jair Cardenas-Salas Lidia Daimiel Emilio Ros Estefanía Toledo Josep M. Manzanares Inmaculada Gonzalez-Monge Miguel-Ángel Muñoz Diego Martinez-Urbistondo Lucas Tojal-Sierra Carlos Muñoz-Bravo Salvador Miralles-Gisbert Marian Martin Antonio García-Ríos Sara Castro-Barquero José Carlos Fernández-García José Manuel Santos-Lozano F. Javier Basterra-Gortari Liliana Gutiérrez-Carrasquilla Patricia Guillem-Saiz Alba Satorres Itziar Abete Carolina Sorto-Sanchez Javier Díez-Espino Nancy Babio Montse Fitó Josep A. Tur |
| author_sort | Cristina Bouzas |
| collection | DOAJ |
| description | Aims: To assess the comparative effects of glucagon-like peptide-1 receptor agonists (GLP-1RA), 4-dipeptidyl peptidase inhibitors (DPP-4I), and metformin treatment during one year on metabolic syndrome (MetS) components and severity in MetS patients. Methods: Prospective study (n = 6165 adults) within the frame of PREDIMED-Plus trial. The major end-point was changes on MetS components and severity after one- year treatment of GLP-1RA, DPP-4I, and metformin. Anthropometric measurements (weight, height and waist circumference), body mass index (BM), and blood pressure were registered. Blood samples were collected after overnight fasting. Plasma glucose, glycosylated hemoglobin (HbA1c), plasma triglycerides and cholesterol were measured. Dietary intakes as well as physical activity were assessed through validated questionnaires. Results: MetS parameters improved through time. The treated groups improved glycaemia compared with untreated (glycaemia ∆ untreated: −1.7 mg/dL(± 13.5); ∆ metformin: − 2.5(± 23.9) mg/dL; ∆ DPP-4I: − 4.5(± 42.6); mg/dL ∆ GLP-1RA: − 4.3(± 50.9) mg/dL; and HbA1c: ∆ untreated: 0.0(± 0.3) %; ∆ metformin: − 0.1(± 0.7) %; ∆ DPP-4I: − 0.1(± 1.0) %; ∆ GLP-1RA: − 0.2(± 1.2) %. Participants decreased BMI and waist circumference. GLP-1RA and DPP-4I participants registered the lowest decrease in BMI (∆ untreated: −0.8(± 1.6) kg/m2; ∆ metformin: − 0.8(± 1.5) kg/m2; ∆ DPP-4I: − 0.6(± 1.3) kg/m2; ∆ GLP-1RA: − 0.5(± 1.2) kg/m2. and their waist circumference (∆ untreated: −2.8(± 5.2) cm; ∆ metformin: − 2.6(± 15.2) cm; ∆ DPP-4I: − 2.1(± 4.8) cm; ∆ GLP-1RA: − 2.4(± 4.1) cm. Conclusion: In patients with MetS and healthy lifestyle intervention, those treated with GLP-1RA and DPP-4I obtained better glycemic profile. Anthropometric improvements were modest. |
| first_indexed | 2024-04-09T21:00:41Z |
| format | Article |
| id | doaj.art-4e717f3ea05f443195b36fb898b12f18 |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-04-09T21:00:41Z |
| publishDate | 2023-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-4e717f3ea05f443195b36fb898b12f182023-03-29T09:24:30ZengElsevierBiomedicine & Pharmacotherapy0753-33222023-05-01161114561Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndromeCristina Bouzas0Rosario Pastor1Silvia Garcia2Margalida Monserrat-Mesquida3Miguel Ángel Martínez-González4Jordi Salas-Salvadó5Dolores Corella6Albert Goday7J. Alfredo Martínez8Ángel M. Alonso-Gómez9Olga Fernández-Barceló10Jesús Vioque11Dora Romaguera12José Lopez-Miranda13Ramón Estruch14Francisco J. Tinahones15José Lapetra16Lluís Serra-Majem17Blanca Riquelme-Gallego18Vicente Martín-Sánchez19Xavier Pintó20Miguel Delgado-Rodriguez21Pilar Matía22Josep Vidal23Jersy-Jair Cardenas-Salas24Lidia Daimiel25Emilio Ros26Estefanía Toledo27Josep M. Manzanares28Inmaculada Gonzalez-Monge29Miguel-Ángel Muñoz30Diego Martinez-Urbistondo31Lucas Tojal-Sierra32Carlos Muñoz-Bravo33Salvador Miralles-Gisbert34Marian Martin35Antonio García-Ríos36Sara Castro-Barquero37José Carlos Fernández-García38José Manuel Santos-Lozano39F. Javier Basterra-Gortari40Liliana Gutiérrez-Carrasquilla41Patricia Guillem-Saiz42Alba Satorres43Itziar Abete44Carolina Sorto-Sanchez45Javier Díez-Espino46Nancy Babio47Montse Fitó48Josep A. Tur49CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands-IUNICS, 07122 Palma de Mallorca, Spain; Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, SpainResearch Group on Community Nutrition & Oxidative Stress, University of Balearic Islands-IUNICS, 07122 Palma de Mallorca, Spain; Faculty of Health Sciences,Catholic University of Avila, 05005 Avila, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands-IUNICS, 07122 Palma de Mallorca, Spain; Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands-IUNICS, 07122 Palma de Mallorca, Spain; Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; University of Navarra, Department of Preventive Medicine and Public Health, IDISNA, 31008 Pamplona, Spain; Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, USACIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Universitat Rovira i Virgili, Biochemistry and Biotechnology Department, Human Nutrition Unit, IISPV, Hospital Universitari de Sant Joan, 43201 Reus, Spain; Unidad de Nutrición, Lípidos y Endocrinologia, Hospital Universitari de Sant Joan de Reus, Institut d′Insvestigacions Sanitàries Pere Virgili (IISPV), 43201 Reus, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Department of Preventive Medicine, University of Valencia, 46100 Valencia, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d′Investigació Mèdica (IMIM), 08003 Barcelona, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Cardiometabolics Precision Nutrition Program, IMDEA Food, CEI UAM + CSIC, 28049 Madrid, Spain; Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, 31008 Pamplona, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country UPV/EHU, 48013 Vitoria, Gasteiz, SpainDepartment of Nursing, School of Health Sciences, University of Malaga, Institute of Biomedical Research in Málaga (IBIMA-University of Malaga), 29071 Málaga, SpainInstituto de Investigación Sanitaria y Biomédica de Alicante, ISABIAL-UMH, 03550 Alicante, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, 14004 Córdoba, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Department of Internal Medicine, IDIBAPS, Hospital Clinic, University of Barcelona, 08036 Barcelona, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Virgen de la Victoria Hospital, Department of Endocrinology, University of Málaga, 29010 Málaga, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, 41013 Sevilla, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Institute for Biomedical Research, University of Las Palmas de Gran Canaria, 35016 Las Palmas, SpainCIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Department of Preventive Medicine, University of Granada, 18071 Granada, SpainCIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Institute of Biomedicine (IBIOMED), University of León, 24071 Leon, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge, Hospital Universitario de Bellvitge, 08907 Barcelona, SpainCIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Department of Health Sciences, Center for Advanced Studies in Olive Grove and Olive Oils, University of Jaen, 23071 Jaen, SpainDepartment of Endocrinology and Nutrition, Instituto de Investigación Sanitaria San Carlos (IdISSC), 28040 Madrid, SpainDepartment of Endocrinology, IDIBAPS, Hospital Clinic, University of Barcelona, 08036 Barcelona, SpainDepartment of Endocrinology, Fundación Jiménez-Díaz University Hospital, 28040 Madrid, SpainNutritional Control of the Epigenome Group, Precision Nutrition and Obesity Program, IMDEA Food, CEI UAM + CSIC, 28049 Madrid, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Lipid Clinic, Department of Endocrinology and Nutrition, Institut d′Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clínic, 08036 Barcelona, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; University of Navarra, Department of Preventive Medicine and Public Health, IDISNA, 31008 Pamplona, SpainUniversitat Rovira i Virgili, Biochemistry and Biotechnology Department, Human Nutrition Unit, IISPV, Hospital Universitari de Sant Joan, 43201 Reus, Spain; Unidad de Nutrición, Lípidos y Endocrinologia, Hospital Universitari de Sant Joan de Reus, Institut d′Insvestigacions Sanitàries Pere Virgili (IISPV), 43201 Reus, SpainDepartment of Preventive Medicine, University of Valencia, 46100 Valencia, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d′Investigació Mèdica (IMIM), 08003 Barcelona, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Cardiometabolics Precision Nutrition Program, IMDEA Food, CEI UAM + CSIC, 28049 Madrid, Spain; Internal Medicine Department, HM Sanchinarro, 28050 Madrid, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country UPV/EHU, 48013 Vitoria, Gasteiz, SpainDivision of Preventive Medicine and Public Health, University of Malaga, Institute of Biomedical Research in Málaga (IBIMA-University of Malaga), Málaga, SpainCentro de Salud El Raval, 03203 Elche, Alicante, SpainHealth Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, 14004 Córdoba, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Department of Internal Medicine, IDIBAPS, Hospital Clinic, University of Barcelona, 08036 Barcelona, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Virgen de la Victoria Hospital, Department of Endocrinology, University of Málaga, 29010 Málaga, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, 41013 Sevilla, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; University of Navarra, Department of Preventive Medicine and Public Health, IDISNA, 31008 Pamplona, SpainUniversitat Rovira i Virgili, Biochemistry and Biotechnology Department, Human Nutrition Unit, IISPV, Hospital Universitari de Sant Joan, 43201 Reus, Spain; Unidad de Nutrición, Lípidos y Endocrinologia, Hospital Universitari de Sant Joan de Reus, Institut d′Insvestigacions Sanitàries Pere Virgili (IISPV), 43201 Reus, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Department of Preventive Medicine, University of Valencia, 46100 Valencia, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d′Investigació Mèdica (IMIM), 08003 Barcelona, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, 31008 Pamplona, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country UPV/EHU, 48013 Vitoria, Gasteiz, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; University of Navarra, Department of Preventive Medicine and Public Health, IDISNA, 31008 Pamplona, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Universitat Rovira i Virgili, Biochemistry and Biotechnology Department, Human Nutrition Unit, IISPV, Hospital Universitari de Sant Joan, 43201 Reus, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d′Investigació Mèdica (IMIM), 08003 Barcelona, SpainCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands-IUNICS, 07122 Palma de Mallorca, Spain; Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain; Correspondence to: Research Group on Community Nutrition and Oxidative Stress, University of the Balearic Islands & CIBEROBN, Guillem Colom Bldg, Campus, E-07122 Palma de Mallorca, Spain.Aims: To assess the comparative effects of glucagon-like peptide-1 receptor agonists (GLP-1RA), 4-dipeptidyl peptidase inhibitors (DPP-4I), and metformin treatment during one year on metabolic syndrome (MetS) components and severity in MetS patients. Methods: Prospective study (n = 6165 adults) within the frame of PREDIMED-Plus trial. The major end-point was changes on MetS components and severity after one- year treatment of GLP-1RA, DPP-4I, and metformin. Anthropometric measurements (weight, height and waist circumference), body mass index (BM), and blood pressure were registered. Blood samples were collected after overnight fasting. Plasma glucose, glycosylated hemoglobin (HbA1c), plasma triglycerides and cholesterol were measured. Dietary intakes as well as physical activity were assessed through validated questionnaires. Results: MetS parameters improved through time. The treated groups improved glycaemia compared with untreated (glycaemia ∆ untreated: −1.7 mg/dL(± 13.5); ∆ metformin: − 2.5(± 23.9) mg/dL; ∆ DPP-4I: − 4.5(± 42.6); mg/dL ∆ GLP-1RA: − 4.3(± 50.9) mg/dL; and HbA1c: ∆ untreated: 0.0(± 0.3) %; ∆ metformin: − 0.1(± 0.7) %; ∆ DPP-4I: − 0.1(± 1.0) %; ∆ GLP-1RA: − 0.2(± 1.2) %. Participants decreased BMI and waist circumference. GLP-1RA and DPP-4I participants registered the lowest decrease in BMI (∆ untreated: −0.8(± 1.6) kg/m2; ∆ metformin: − 0.8(± 1.5) kg/m2; ∆ DPP-4I: − 0.6(± 1.3) kg/m2; ∆ GLP-1RA: − 0.5(± 1.2) kg/m2. and their waist circumference (∆ untreated: −2.8(± 5.2) cm; ∆ metformin: − 2.6(± 15.2) cm; ∆ DPP-4I: − 2.1(± 4.8) cm; ∆ GLP-1RA: − 2.4(± 4.1) cm. Conclusion: In patients with MetS and healthy lifestyle intervention, those treated with GLP-1RA and DPP-4I obtained better glycemic profile. Anthropometric improvements were modest.http://www.sciencedirect.com/science/article/pii/S0753332223003499Metabolic syndromeGlucagon-like peptide 1 agonistsGLP-1RA4-dipeptidyl peptidase inhibitorsDPP-4I |
| spellingShingle | Cristina Bouzas Rosario Pastor Silvia Garcia Margalida Monserrat-Mesquida Miguel Ángel Martínez-González Jordi Salas-Salvadó Dolores Corella Albert Goday J. Alfredo Martínez Ángel M. Alonso-Gómez Olga Fernández-Barceló Jesús Vioque Dora Romaguera José Lopez-Miranda Ramón Estruch Francisco J. Tinahones José Lapetra Lluís Serra-Majem Blanca Riquelme-Gallego Vicente Martín-Sánchez Xavier Pintó Miguel Delgado-Rodriguez Pilar Matía Josep Vidal Jersy-Jair Cardenas-Salas Lidia Daimiel Emilio Ros Estefanía Toledo Josep M. Manzanares Inmaculada Gonzalez-Monge Miguel-Ángel Muñoz Diego Martinez-Urbistondo Lucas Tojal-Sierra Carlos Muñoz-Bravo Salvador Miralles-Gisbert Marian Martin Antonio García-Ríos Sara Castro-Barquero José Carlos Fernández-García José Manuel Santos-Lozano F. Javier Basterra-Gortari Liliana Gutiérrez-Carrasquilla Patricia Guillem-Saiz Alba Satorres Itziar Abete Carolina Sorto-Sanchez Javier Díez-Espino Nancy Babio Montse Fitó Josep A. Tur Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome Biomedicine & Pharmacotherapy Metabolic syndrome Glucagon-like peptide 1 agonists GLP-1RA 4-dipeptidyl peptidase inhibitors DPP-4I |
| title | Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome |
| title_full | Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome |
| title_fullStr | Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome |
| title_full_unstemmed | Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome |
| title_short | Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome |
| title_sort | comparative effects of glucagon like peptide 1 receptors agonists 4 dipeptidyl peptidase inhibitors and metformin on metabolic syndrome |
| topic | Metabolic syndrome Glucagon-like peptide 1 agonists GLP-1RA 4-dipeptidyl peptidase inhibitors DPP-4I |
| url | http://www.sciencedirect.com/science/article/pii/S0753332223003499 |
| work_keys_str_mv | AT cristinabouzas comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT rosariopastor comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT silviagarcia comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT margalidamonserratmesquida comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT miguelangelmartinezgonzalez comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT jordisalassalvado comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT dolorescorella comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT albertgoday comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT jalfredomartinez comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT angelmalonsogomez comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT olgafernandezbarcelo comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT jesusvioque comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT doraromaguera comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT joselopezmiranda comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT ramonestruch comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT franciscojtinahones comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT joselapetra comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT lluisserramajem comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT blancariquelmegallego comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT vicentemartinsanchez comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT xavierpinto comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT migueldelgadorodriguez comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT pilarmatia comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT josepvidal comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT jersyjaircardenassalas comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT lidiadaimiel comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT emilioros comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT estefaniatoledo comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT josepmmanzanares comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT inmaculadagonzalezmonge comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT miguelangelmunoz comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT diegomartinezurbistondo comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT lucastojalsierra comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT carlosmunozbravo comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT salvadormirallesgisbert comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT marianmartin comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT antoniogarciarios comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT saracastrobarquero comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT josecarlosfernandezgarcia comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT josemanuelsantoslozano comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT fjavierbasterragortari comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT lilianagutierrezcarrasquilla comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT patriciaguillemsaiz comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT albasatorres comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT itziarabete comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT carolinasortosanchez comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT javierdiezespino comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT nancybabio comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT montsefito comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome AT josepatur comparativeeffectsofglucagonlikepeptide1receptorsagonists4dipeptidylpeptidaseinhibitorsandmetforminonmetabolicsyndrome |